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ABSTRACT
Objectives  To perform ﬁ  ne mapping of the autoimmunity 
susceptibility gene BLK and identify functional variants 
involved in systemic lupus erythematosus (SLE).
Methods  Genotyping of 1163 European SLE patients and 
1482 controls and imputation were performed covering 
the BLK gene with 158 single-nucleotide polymorphisms. 
Logistic regression analysis was done using PLINK 
and conditional analyses using GENABEL’s test score. 
Transfections of BLK constructs on HEK293 cells 
containing the novel mutation or the wild type form were 
analysed for their effect on protein half-life using a protein 
stability assay, cycloheximide and western blot. CHiP-qPCR 
for detection of nuclear factor κ B (NFkB) binding.
Results  Fine mapping of BLK identiﬁ  ed two 
independent genetic effects with functional 
consequences: one represented by two tightly linked 
associated haplotype blocks signiﬁ  cantly enriched for 
NFκB-binding sites and numerous putative regulatory 
variants whose risk alleles correlated with low BLK 
mRNA levels. Binding of NFkBp50 and p65 to an 
associated 1.2 Kb haplotype segment was conﬁ  rmed. 
A second independent genetic effect was represented 
by an Ala71Thr, low-frequency missense substitution 
with an OR=2.31 (95% CI 1.38 to 3.86). The 71Thr 
decreased BLK protein half-life.
Conclusions  These results show that rare and common 
regulatory variants in BLK are involved in disease 
susceptibility and both, albeit independently, lead to 
reduced levels of BLK protein.
INTRODUCTION
The BLK gene located on chromosome 8p23-p22 
encodes a tyrosine kinase of the SRC family of 
proto-oncogenes. A genome-wide association 
study identiﬁ  ed a single-nucleotide polymorphism 
(SNP) rs13277113 in the 5′ upstream region associ-
ated with systemic lupus erythematosus (SLE),1 a 
chronic autoimmune disease with complex inheri-
tance. To date, multiple studies have conﬁ  rmed the 
association of BLK with SLE in European and Asian 
populations as well as with other autoimmune 
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disorders.2–10 BLK protein has 505 amino acids with 
SH3 (58–118), SH2 (124–220) and protein kinase 
domains (241–494). Although BLK is expressed in 
various tissues such as pancreatic β cells, thymus, 
hair follicles and salivary ducts,11 12 it is preferen-
tially expressed in B lymphoid cells and has a role in 
B cell receptor signalling and B cell development.13
The BLK-rs13277113 SNP is part of a group of 
common variants across several genes that have 
been associated with SLE through genome-wide 
association study.14 Together, they account for 15% 
of the disease’s familial aggregation and few have 
been demonstrated to be functional.14 The SLE-
risk allele rs13277113-A correlated with decreased 
expression of BLK mRNA1 but the mechanism by 
which this or another SNP in linkage disequilib-
rium (LD) with it affects gene expression has not 
been characterised yet.
To address which and if common and/or low 
frequency functional variants are involved in SLE 
susceptibility at the BLK locus, we performed 
ﬁ   ne mapping by genotyping tag SNPs aided by 
imputation.
METHODS
Patients and controls
After quality control of the data, the study sam-
ple consisted of 1163 patients with SLE and 1482 
ethnicity-matched healthy control subjects from 
the European multicentre collaboration network 
BIOLUPUS (supported by the European Science 
Foundation), comprising individuals from Argentina 
(60 patients and 109 controls), Belgium (70 patients 
and 59 controls), Germany (284 patients and 176 
controls), Hungary (38 patients and 35 controls), 
Italy (264 patients and 320 controls), Portugal (163 
patients and 165 controls), Spain (206 patients and 
227 controls) and Sweden (78 patients and 391 con-
trols). A completely new and independent set of 
1103 healthy Spanish controls was also used. All 
patients fulﬁ  lled at least four of the American College 
of Rheumatology 1982 criteria for the classiﬁ  cation 
of SLE.15 Subjects with an individual genotyping 
rate lower than 90% or duplicated and/or related 
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populations together (phase 3, release 2) and haplotypes of the 
CEU population from the pilot phase of 1000 Genomes Project20 
(downloaded from http://mathgen.stats.ox.ac.uk/impute/
impute_v2.html#ﬁ   ltered_1kg_hm3_haps on May 13th, 2011). 
HapMap haplotypes duplicated with 1000 Genomes data were 
removed. Default parameters were used and the Ne argument 
set to 15 000. Only imputed genotypes with a probability equal 
to or greater than 0.9, a minor allelic frequency (MAF) equal to 
or greater than 0.005, following Hardy–Weinberg equilibrium 
(p>0.001), and a genotyping rate equal to or greater than 0.95 
were retained for association.
Statistical analysis
Genetic association analysis was done using PLINK v1.0721 and 
GenABEL v1.6-5.22 All SNPs with a genotype call rate <95% or 
not in Hardy–Weinberg equilibrium (p<0.001) were excluded. For 
single-marker tests, we performed a Cochran-Mantel-Haenszel 
(CMH) meta-analysis, using the country of origin as the stratiﬁ  ca-
tion variable, and a Breslow-Day test to assess homogeneity of 
the ORs. p Values were adjusted using false discovery rate. We 
also performed an omnibus haplotype test for all windows of 2, 3 
and 4 SNPs across the gene. In this test, the alternate hypothesis 
of each haplotype having a unique effect is compared with the 
null hypothesis (df=number of haplotypes-1).21 Omnibus as well 
as haplotype-speciﬁ  c tests for haplotype blocks were conducted 
by testing each haplotype against all others pooled together (1 df). 
A Bonferroni correction using the number of windows tested was 
applied (p<0.05/323 windows tested).
Conditional analysis was done by logistic regression using 
GenABEL’s score test. By specifying the country of origin as 
samples were excluded. We removed individuals with <90% of 
European ancestry, as estimated with STRUCTURE v2.3.3 and 
350 ancestry informative markers.
Tag SNP selection
From the LD structure of the BLK locus in the HapMap CEU 
population (data release 27; available at http://hapmap.ncbi.
nlm.nih.gov/), tag SNPs selection capturing more than 90% of 
common variation at the gene locus (minor allele frequency of 
greater than or equal to 10%) including 20 kb upstream and 
downstream of the gene, at a r2 threshold of greater than or equal 
to 0.8, were selected using the tagger algorithm implemented in 
Haploview, V.4.1.16 After quality control of the data, 27 tag SNPs 
were used for genotyping and to guide the imputation.
Genotyping
All samples were genotyped at the Feinstein Institute for Medical 
Research (Manhasset, New York, USA) using a GoldenGate 
Custom Genotyping Assay and a BeadXpress Reader from 
Illumina (San Diego, California, USA). Two SNPs (rs1478895 
and rs2248932) were genotyped by TaqMan 5′-exonuclease 
assay (ABI, Foster City, California, USA). SNP rs55758736 was 
genotyped by RFLP and sequencing for veriﬁ  cation in 178 indi-
viduals. An Illumina custom BeadArray was used for genotyping 
this SNP in 1103 healthy controls.
Imputation
We used IMPUTE217 across a 250 kb genomic region 
(chr8:11,288,930-11,559,517) of the BLK locus. As reference 
panels we used haplotypes from all HapMap Consortium18 19 
Figure 1  Systemic lupus erythematosus-associated single-nucleotide polymorphisms (SNPs) and haplotype blocks and genomic features of the 
BLK locus. From top to bottom: –log10 of the p value corrected by false discovery rate for 158 SNPs. Below, the association for haplotype windows 
of two, three and four SNPs is displayed; the horizontal black line marks the threshold for Bonferroni correction (p=0.05/323 windows tested). Only 
SNP windows contained within block B1 (5′ upstream, exon 1 – UTR – and beginning of intron 1), B3 (end of intron 1) and B5 (exons 4, 5 and 6) were 
associated after correction. The exon/intron structure of BLK is displayed next and then NFkBp65 (blue), IRF4 (yellow) and PAX5 (green) Chip-Seq 
identiﬁ  ed binding sites and promoter-associated histone marks (H3K4Me3) according to ENCODE project. Recombination rate (cM/Mb) is displayed at 
the bottom.
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the strata argument, we performed a structured test of associ-
ation for all SNPs. In a stepwise manner, the SNP with higher 
p value was identiﬁ  ed in each step and then used as covariate 
for the next association step until no SNP remained associ-
ated. GenABEL package was run using R version 2.9.2.
Genome sequence track analysis for epigenomic marks and 
transcription factor binding sites
Associated and non-associated SNPs within haplotype blocks 
were analysed for enrichment with eight epigenomic marks 
using GenomeRunner.23 For SNPs within each haploblock the 
same number of randomly selected nucleotides from the whole 
range of haploblocks within chr8:11374997-11475653 coordi-
nates (NCBI36/hg18 genome assembly) was sampled over the 
course of 100 Monte-Carlo simulations. The average expected 
frequency of their association with a given genomic feature 
(eg, nuclear factor κ B (NFkB) binding site, epigenomic marks) 
was compared with the observed frequency using a χ2 test. 
Speciﬁ  cally, SNPs within haploblocks were tested for enrich-
ment against experimentally validated NFκBp65, IRF4 and PAX5 
transcription factor binding sites annotated in the wgenco-
deregtfbs clustered UCSC table of the genome browser.24 Other 
tables included histone acetylation and methylation marks 
(Regulation/Broad histone tables for Gm12878 lymphoblastoid 
cell line). p Values were –Log10 converted and a – was included 
for under-represented p values. The values are shown as a heat-
map plotted using Matlab (Natick, Massachusetts, USA) (online 
ﬁ  gure S2). p Values are presented in the online table S3.
We used SIFT25 to predict the status of rs55758736. SIFT pre-
dicts whether an amino acid substitution affects protein function 
based on similarity to related sequences and physical properties 
of amino acids (http://sift.jcvi.org/).
Figure 2  Structure of associated BLK haplotypes. (A) Haplotypes formed by single-nucleotide polymorphisms (SNPs) in each associated block 
B1, B3 and B5 as estimated with expectation maximisation algorithm (Haploview v.4.1). Blue and red squares represent major and minor alleles, 
respectively. To the right of each haplotype, its population frequency (cases and controls) and connections between blocks (thin lines if >1%, thick 
lines if >10%) are displayed. In crossing areas are the values of the multiallelic D′ which represent the level of recombination between two blocks. 
See table 1 for haplotype-speciﬁ  c ORs and p values. Haplotypes associated with increased risk of developing systemic lupus erythematosus are 
enclosed within rectangles (solid line if p<1×10−3; dashed line if p<0.05). B1 contains a risk haplotype tagged by rs998683-A(b) (strongest hit 
in this study) and its proxies including the rs13277113-A allele(a) previously described.1 Blocks B1 and B3 are highly correlated. B3 contains SNP 
rs9329246(c), which is shared by the two strongest four-SNP windows of the whole BLK locus. B5 contains the independent risk haplotype tagged by 
the mutant allele of the rs55758736/Ala71Thr non-synonymous SNP(d) and a set of highly correlated allelic variants (grey circles). The independence 
of B5 risk haplotype is further supported by (B) the linkage disequilibrium plot displaying r2 values between the representative variants of each block 
and (C) the relationship between their alleles.
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CHiP-qPCR for NFkB p50 and p65 on the 1.2 Kb associated 
haplotype genomic segment
CHiP experiments were performed according to the manufac-
turer’s recommendations (EZ-Magna CHiP A, Millipore, Billerica, 
California, USA). In brief, 4×10−6 Daudi cells were incubated 
with or without 10 mg/ml anti-immunoglobulin M (IgM) F(ab′)2 
fragments (Jackson Immunoresearch, West Grove, Pennsylvania, 
USA) for the indicated time. Cells were ﬁ  xed with 1% formal-
dehyde and nuclei were isolated and sonicated within 300 ml of 
lysis buffer. An amount of 50 ml of chromatin–protein complexes 
were immunoprecipitated overnight at 4°C by mild agitation with 
5 mg of pAb speciﬁ  c for p65 (Santa Cruz, California, USA) or p50 
(Abcam, Cambridge, Massachusetts, USA) or normal rabbit IgG 
(Millipore) as negative control. After elution from the immunopre-
cipitated chromatin complexes followed by reverse-crosslink and 
cleanup, DNA samples were subjected to real-time PCR analysis 
using primers as follows: rs2248932 neighbouring region within 
Blk intron 1 primer set: forward – TGCATCAGCATCACTGGG; 
reverse – GGCACAATAGTTCTGAAACCTC. IkBa was 
used as control for NFkB binding with the following primer 
set: forward – CACTTGCAGAGGGACAGGAT; reverse 
– GAGAAACTCCCTGCGATGAG.
Cloning and expression of BLK constructs with the 
Ala71Thr substitution
BLK sequence was PCR ampliﬁ  ed using cDNA from a BJAB 
cell line and primers f-BLK: 5′-CACCatggggctggtaagtagc-3 
and r-BLK 5′-gggctgcagctcgtactgcc-3. The start codon in the 
forward primer is underlined. The open reading frame was 
cloned in pcDNA3.1D/V5-His (Invitrogen, Life Technologies, 
Grand Island, New York, USA) and conﬁ   rmed by sequenc-
ing. The protein tagged with the V5 epitope at the C terminal 
was produced by deletion of the stop codons. The BLK 71Thr 
isoform was produced by mutagenesis PCR with pfu-Ultra 
II fusion HS polymerase (Stratagene, Agilent Technologies, 
Santa Barbara, California, USA) and the primers BLKm71f: 
5′-TATGACTACACCaCTATGAATGATCGGGACCT-3 and 
BLKm71r: 5′-ATCATTCATAGtGGTGTAGTCATACAGAG-3. 
Expression of the constructs was assayed by western blot with 
anti-V5 antibody (online ﬁ  gure S4).
Protein stability assay
Embryonic kidney HEK293T cells grown in RPMI 1640 medium 
supplemented with 10% fetal calf serum were seeded on six-
well plates and transfected with 4 μg of expression plasmids 
V5-tagged BLK isoforms using Lipofectamine 2000. At 22 h cells 
were harvested and distributed in six wells of 12-well plates. 
After 2 h cells were treated with 20 μg/ml cycloheximide in dim-
ethyl sulphoxide (DMSO) or DMSO alone (time 0) for various 
times. Cellular extracts were prepared in lysis buffer: 1% NP40, 
150 mM NaCl, 10 mM Tris (pH 7.5), 2 mM sodium orthova-
nadate, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfo-
nyl ﬂ  uoride and protease and phosphatases inhibitor cocktails 
(Roche). A ﬁ  fth of the extract was resolved on SDS-PAGE and 
immmunoblotting carried out using standard protocols with 
anti-V5 antibodies (Invitrogen), b-tubulin (Sigma-Aldrich) and 
antimouse IgG-HRP (Zymed, San Francisco, California, USA). 
Quantiﬁ  cation of the bands was done using ImageJ.
Figure 3  CHiP-qtPCR showing binding of NFκB p50 as well as NFκBp65 within the genomic segment contained in the 1.2 Kb haplotype window 
in Daudi cells. (A) mRNA expression of the BLK gene after BcR stimulation. (B) qtPCR of the portion containing SNP rs2248932 within the 1.2 kb 
genomic segment in intron 1 of human BLK. (C) qtPCR of the IkBa gene used as positive control.
20_annrheumdis-2011-200987.indd   1222 20_annrheumdis-2011-200987.indd   1222 5/29/2012   10:36:28 AM 5/29/2012   10:36:28 AMBasic and translational research
Ann Rheum Dis 2012;71:1219–1226. doi:10.1136/annrheumdis-2011-200987 1223
RESULTS
Fine mapping and conditional analysis of BLK reveals two 
independent effects
A total of 158 SNPs with MAF>0.005 were tested for asso-
ciation in 1163 European patients with SLE and 1482 age- 
and country-of-origin-matched controls. A meta-analysis 
demonstrated that the strongest association signal was in 
the BLK promoter region (rs998683, PCMH-corrected=1.05×10−4 
and OR 1.38 (1.21 to 1.58)) (online table S1). However, even 
after correction for multiple testing, multiple association sig-
nals across the gene remained signiﬁ  cant. To reﬁ  ne the BLK 
association, we tested sliding windows, which narrowed it 
down to three blocks (denominated B1, B3 and B5 in ﬁ  gure 
1). The best model of association was observed for a 1.2 kb 
haplotype window between SNPs rs2248932 and rs9329246 
located at the end of BLK’s ﬁ  rst intron (p=1.58×10−10, omni-
bus haplotype test).
The ﬁ  rst block (B1) covered BLK 5′ upstream region, exon 
1 (untranslated-UTR) and beginning of intron 1, which corre-
spond to the promoter. This block comprised a set of highly cor-
related SNPs including all variants previously associated with 
SLE (rs2409780, rs2618444, rs2736336, rs2736337, rs2736338, 
rs2736340, rs13277113) and our strongest hit (rs998683) (ﬁ  gure 
2A and online ﬁ  gure S1). Haplotype-speciﬁ  c analysis demon-
strated a common, risk haplotype tagged by the minor alleles of 
these SNPs, including the rs13277113-A variant (omnibus test p 
value=1.61×10−5, OR=1.32 (1.16 to 1.49)) (table 1).
The second block (B3) was at the end of intron 1 (ﬁ  gure 1) 
and displayed moderate LD with B1 (ﬁ  gure 2A). Consistent with 
this observation, a risk haplotype correlated with the promoter 
risk haplotype and with similar haplotype frequency was over-
represented in cases, although only with nominal association 
(p=0.013) (table 1).
In addition, an independent and low-frequency-haplotype 
within B3 (1.1% in controls) was strongly associated and 
had a large effect size (p=5.16×10−7, OR=2.75 (1.80 to 
4.19)) (table 1). This haplotype correlated completely with 
a risk haplotype observed on the third associated block B5 
(p=1.57×10−4, OR=2.48 (1.54 to 4.00)), which covered the 
protein-coding exons 4, 5 and 6 (ﬁ  gure 1). The minor alleles 
of six low-frequency variants occurred in this haplotype: 
rs55758736, a non-synonymous SNP in exon 4 resulting 
in an alanine to threonine substitution at amino acid posi-
tion 71 (Ala71Thr; GCT>aCT); chr8:11443817 (intron 4); 
chr8:11444706 (intron 5), chr8:11446229 (intron 5); and chr8: 
8-11446791 and rs2255227 (intron 6) (ﬁ  gure 2A).
Conditional analysis using multivariate logistic regression 
demonstrated that the association of SNPs in B3 disappeared 
after adjusting by the strongest hit located in B1 (rs998683) sug-
gesting that the B3 and the B1 association was not independent 
(online table S2).
In contrast, the low-frequency associated SNPs located 
in B5 remained associated after adjustment to rs998683 
supporting two independent effects in BLK. Further, we 
observed that SNP rs55758736 had an r2≈0 with SNPs tag-
ging B1 and B3 (figure 2B,C and online table S2), although 
this may be an underestimation due to the low frequency 
of the SNP.
Figure 4  Genotyping of the Ala71Thr substitution in exon 4 of BLK. (A) Schematic diagrams showing the procedure for genotyping the 
single-nucleotide polymorphism (SNP) rs55758736 in exon 4 of BLK. Genomic DNA was ampliﬁ  ed with primers ﬂ  anking exon 4 (In3-F: 
5′AGAAGCCTGTCCTCCTTGGTAGC 3′ and In4-R: 5′GGAAAGATTTTGGAGAGGAAGACA 3′) and the PCR products were digested with the 
restriction enzyme AciI. The A allele disrupts the restriction site generating only two fragments of 48 and 322 bp while the G allele produces three 
fragments of 48, 80 and 242 bp. (B) PCR products of four subjects showing a unique band of 370 bp and (C) the subsequent AciI digestion of the 
ampliﬁ  cation products. Subjects 2 and 3 are heterozygotes (G/A) and subjects 1 and 4 are homozygotes for the wild type allele (G/G). (D) Sequence 
chromatographs showing one subject heterozygous for the BLK mutation (above) and one subject homozygous for the wild type allele (below).
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Analysis of epigenetic marks and transcription factor binding 
sites shows an over-representation of NFkB and IRF4 along the 
promoter region associated blocks
We ﬁ  rst attempted the identiﬁ  cation of functional regulatory vari-
ants across the promoter blocks B1 and B3. Bioinformatic analysis 
revealed that B1 was signiﬁ  cantly enriched for H3K4me3 sites, a 
hallmark of active promoters (ﬁ  gure 1, online ﬁ  gure S2 and online 
table S3). Furthermore, SNPs in B1 and B3, when compared with 
randomly chosen nucleotides, were enriched for binding sites for 
the transcription factor NFκBp65 and IRF4 but not PAX5 (using 
data from ENCODE project Chip-Seq for lymphoblastoid cell 
lines), while SNPs in the non-associated blocks B2 and B4 were 
not (ﬁ  gure 1, online ﬁ  gure S2 and online table S3). However, we 
were unable to single out a unique variant to explain the correla-
tion between low BLK gene expression and risk alleles of SNPs 
in B1 and B3 due to the strong LD. We hypothesised that mul-
tiple sites would therefore explain a coordinated regulatory effect 
on the expression of BLK. Nevertheless, the 1.2 Kb haplotype 
window with the strongest genetic association and within B3 
contained SNP rs2248932 that overlapped with a DNAse hyper-
sensitive cluster and with a strong NFκB binding site (online ﬁ  gure 
S3 and online table S4). To conﬁ  rm if NFκB binds to this segment 
of BLK we performed a CHiP-qtPCR experiment in a human 
Daudi cell line (ﬁ  gure 3A–C). We observed that NFκBp50 binds 
somewhat earlier than NFκBp65 (30 min post-BcR stimulation). 
The IkBa promoter served as control (ﬁ  gure 3C). Simultaneously, 
expression of BLK is reduced after activation (ﬁ  gure 3A).
The 71Thr mutation leads to reduced half-life of BLK protein
The independent Ala71Thr substitution is located on the SH3 (Src 
homology 3) domain of the BLK protein, which is of importance 
in protein–protein interactions. The SIFT algorithm25 26 predicted 
this substitution to be potentially damaging. As rs55758736 was 
identiﬁ  ed through imputation, we veriﬁ  ed the presence of the 
mutation in 178 selected samples of cases and controls. Of these, 
we genotyped all of those individuals predicted by imputation 
to have the mutation and a group of individuals predicted not 
to have it. Veriﬁ  cation was done using PCR, RFLP and sequenc-
ing (ﬁ   gure 4) reaching 92% concordance. The mutation was 
observed in 2.17% of SLE patients and 0.92% of controls, all in 
the heterozygous state (OR=2.31; 95% CI 1.38 to 3.86 with the 
Pearson’s goodness-of-ﬁ  t χ2 (df=1)). Adding 1103 new controls, 
the OR was adjusted to 1.79 (95% CI 1.15 to 2.51).
At the translational level, the substitution of alanine for threo-
nine implies the formation of a putative phosphorylation site 
that could lead to the reduction of the half-life of the protein. We 
investigated if this was the case. Using constructs containing each 
allele of rs55758736 in transfection experiments we observed 
that, indeed, 71Thr had an accelerated degradation after treat-
ment with the protein synthesis inhibitor cycloheximide as com-
pared with the Ala71 allele (ﬁ  gure 5 A,B and ﬁ  gure S4).
DISCUSSION
We have herein shown that blocks of associated SNPs within the 
promoter regions of the BLK gene were signiﬁ  cantly enriched 
for NFκB and IRF4 binding sites, potentially involved in regulat-
ing levels of BLK mRNA and the related reduction in BLK gene 
expression levels correlating with the risk haplotypes. Also, 
through conditional analysis we have identiﬁ  ed a potentially 
deleterious, low-frequency mutation leading to reduced BLK 
protein half-life. Unlike the wild type allele, the threonine resi-
due of the mutated variant is capable of being phosphorylated, 
Table 1  Haplotype analysis of the BLK-associated blocks
Block (SNPs)/Start-End (Size) No. SNPs Omnibus test Haplotype Frequency Cases Frequency Controls OR (95% CI) P-value
B1 (rs2409780-rs2618478) 21 1.75E-04
11374997-11393411 (18.4 kb) TACGGTAGCTGTAGGGGCCGA 0.079 0.073 ns 0.4517
CCCGTCCGTTATAGGAGCCGA 0.299 0.245 1.32 (1.16-1.49) 1.61E-05
TACGGTAGCTGTAGGGGCGGA 0.504 0.559 0.81 (0.73-0.91) 7.56E-05
TATAGTAACCGCCCAGAGCAA 0.011 0.014 ns 0.3503
TATAGTAACCGCCCAGAGCAC 0.108 0.109 ns 0.9182
            
B3 (rs58373594-8-11433666) 17 3.85E-07
11428036-11433666 (5.6 kb) ATCGCATAGAGTAAAAG 0.489 0.541 0.80 (0.72-0.89) 2.70E-04
TTGGCATCCAATAGAAG 0.113 0.113 ns 0.9928
AACACACAGGACAGTAG 0.045 0.045 ns 0.9493
AACACACAGGACGGTAG 0.323 0.290 1.13 (1.01-1.27) 0.013
AACACATAGGACAGTAG 0.030 0.011 2.75 (1.80-4.19) 5.16E-07
Strongest window
(rs2248932-rs9329246) / 
11429059-11430289 (1.2 kb)
4 1.58E-10       
B5 (rs2244931-rs17744726) 15 2.56E-04
11441178-11449232 (8.1 kb) CAAGAGTACCGTTTA 0.291 0.328 0.84 (0.75-0.95) 3.94E-03
CGAGGGCACCGTATG 0.134 0.110 1.26 (1.06-1.49) 0.011
GAAGAGTACCGTATG 0.014 0.010 ns 0.2331
CAAGAGTACCGTATG 0.061 0.067 ns 0.3859
GGAGGGCACCGTATG 0.370 0.362 ns 0.5478
GAAGGGTACCGTATG 0.077 0.078 ns 0.8688
CAAGGGTACCGTATG 0.012 0.010 ns 0.6186
GGAGGGTACCGTATG 0.019 0.024 ns 0.236
    CAAAAATATTTCATG 0.023 0.010 2.48 (1.54-4.00)  1.57E-04
The ﬁ  rst column indicates the block for which the haplotype analysis corresponds to. For each block, the ﬁ  rst and the last SNP, the starting and ending positions, as well as the size 
in kilobases (kb) are also presented. The Omnibus P value indicates the overall signiﬁ  cance of the association of the block. Only haplotypes with frequencies equal to or greater than 
0.01 were tested. For the haplotype-speciﬁ  c analyses, the odds ratio (OR) with 95% conﬁ  dence interval (95% CI) and P-values were determined for each haplotype tested against all 
of the others pooled together. In block B3, the SNPs comprising the strongest associated window are underlined and the omnibus test for this window is presented. All analyses were 
performed using PLINK software, version 1.07. ns: non-signiﬁ  cant
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and there is evidence that while phosphorylation sites are 
important for activation of proteins in signal transduction path-
ways phosphorylation sites can act at the same time as signals 
for degradation by ubiquitin ligases.27 28
Protein stability has been extensively studied in the cycling 
protein family. The abundance of cycling E is controlled by 
phosphorylation-triggered ubiquitin-dependent proteolysis.29 30 
Phosphorylation of the Thr380 allows cycling E to be recogn-
ised by Fbw7, an F box protein substrate of related E3 ubiquitin 
ligases.31 Mutation of this Thr380 to Ala prevents degradation of 
cyclin E.32 We are currently investigating if the reduction of the 
half-life of the BLK 71Thr protein is due to an active process of 
degradation mediated by phosphorylation or just the result of a 
general decrease in protein stability.
As the LD within the promoter blocks of BLK was very tight, 
it was not possible for us to deﬁ  ne a single variant that could 
explain the correlation between low BLK levels and a polymor-
phism. Instead, we observed a clear correlation between associ-
ated blocks and transcription factor binding sites for NFκB as 
experimentally determined by ChIP-Seq and contained in the 
ENCODE site. However, the database contains only NFkBp65 
experiments. NFkBp65 is known to have a after BcR activation. 
Alternatively, NFkBp50 homodimers that lack a transactivating 
domain bind to the human BLK promoter, as has been shown 
Figure 5  Reduced half-life of BLK protein in the presence of the 
71Thr mutation. (A) Plasmids expressing each of the two BLK isoforms 
fused with V5 were transfected into HEK293T cells. Twenty-four hours 
after transfection, the cells were treated with 20 µg/ml cycloheximide 
(CHX) for various times as indicated. The recombinant proteins were 
detected by western blot using anti-V5 antibody. Tubulin was used as 
loading control. (B) Quantiﬁ  cation of the blots from three independent 
experiments; the SD at each time point is represented by bars. After 8 h 
of inhibition of protein synthesis, the level of BLK 71Thr was reduced to 
half while the wild type isoform Ala71 remained highly stable.
in mice.33 Here, homodimers of NFκB/p50 were shown to com-
pete with Pax5 and reduce Blk gene expression upon mature B 
cell activation and development to antibody-producing plasma 
cells,33 opposite to what occurs during early B cell differentiation, 
when Blk expression plays an important role.33 We also do not 
know the role of IRF4 in this context and a much more detailed 
analysis of the regulatory landscape of BLK is required to under-
stand the correlation between the promoter risk haplotypes and 
lowered BLK gene expression. Also, due to the strong LD within 
the promoter haplotypes, it has also not been possible to discard 
the region proximal to the C8orf13 or FAM167A region lying 
5′ of BLK. In this context, the same associated SNPs correlate 
with increased levels of FAM167A gene expression.1 The mean-
ing of this is currently unknown and there is no knowledge that 
this gene would have any role in immunity in general. In this 
context, we chose not to include the FAM146A gene in our ﬁ  ne 
mapping, as ours and the actual evidence in other autoimmune 
diseases support BLK as the susceptibility gene in this locus.
We propose that subtle quantitative differences between risk 
and protective haplotypes occur during mature B cell stimula-
tion leading to lower BLK levels, and that epigenetically several 
sites show a variegated effect of NFκBp50 homodimers on the 
promoter region of BLK. Nevertheless, our genetic analysis did 
show a potentially unique location within the highly associ-
ated 1.2 Kb haplotype window where a single binding site for 
NFκBp65 was shown to be particularly strong in the ENCODE 
data and conﬁ  rmed here for NFκBp50 as well.
In summary, we identiﬁ  ed two independent effects within 
the BLK locus one of which covers the promoter region of the 
gene where the associated haplotype blocks are enriched for 
transcription factor binding sites for NFκB and IRF4, providing 
a potential mechanism for the correlation of the risk alleles and 
reduced levels of BLK expression. We also identiﬁ  ed a novel 
mutation where the SLE-associated 71Thr leads to the reduced 
half-life of BLK protein.
What effect reduced BLK expression has on the function of 
human B lymphocytes is at present under investigation.
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